Filing Flows › Guardant Health (GH) › Q1 2025
Guardant Health (GH) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 30, 2025
Guardant Health (GH) reported revenue of $203M for the first quarter 2025 (Q1 2025), +21% from a year earlier and +0.8% from the quarter before. Operating margin was -54.6%, net loss $95.2M (46.8% of revenue).
Guardant Health, Q1 2025: revenue $203M (+21% year over year), operating margin -54.6%, net loss $95.2M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $203M | +0.8% | +21% |
| Operating profit | −$111M | — | — |
| Net earnings | −$95.2M | — | — |
| Operating cash flow | −$62.7M | — | — |
What changed
Revenue was $203.5M in Q1 2025, up 21% year over year and up 1% from the previous quarter. Oncology was the largest line at 74% of revenue. Oncology added $24.8M year over year (up 20%), 71% of the total change. Licensing and other declined 64%.
Operating costs exceeded revenue by $111.0M, an operating margin of -54.6%. Total costs grew 17% against revenue growth of 21%. The fastest-growing cost line was Sales & marketing (+30%). The quarter ended with a net loss of $95.2M, narrower than the previous quarter's $111.0M loss.
Operating cash flow was −$62.7M. Non-cash charges added back $10.2M of depreciation and amortization and $37.8M of share-based compensation. Working capital and other items used $15.5M. Capital expenditures of $4.5M exceeded it, leaving free cash flow of −$67.1M.
Questions
What was Guardant Health's revenue in the first quarter 2025?
Guardant Health (GH) reported revenue of $203M for the first quarter 2025 (Q1 2025), +21% from a year earlier and +0.8% from the quarter before.
Was Guardant Health profitable in the first quarter 2025?
Operating loss was $111M (-54.6% of revenue) and net loss $95.2M.
Source: Guardant Health 10-Q on SEC EDGAR.